NEWS
Announcement of Appointments at the BMC
The Biologics Manufacturing Centre (BMC) Inc. appoints Andy Sheldon as Chief Executive Officer and Elizabeth Douville as Vice President, Corporate Development.
MONTRÉAL, April 7, 2026 -The Biologics Manufacturing Centre (BMC) Inc. today announced the appointment of Andy Sheldon as Chief Executive Officer and Elizabeth Douville as Vice President, Corporate Development, strengthening the organization’s leadership as it advances Canada’s biomanufacturing and pandemic preparedness objectives.
Following a period of leadership continuity, the Board of Directors has confirmed Mr. Sheldon’s appointment as permanent CEO. Mr. Sheldon has served in the role on an interim basis since June 2025.
“Andy has provided steady, credible leadership during a critical period for BMC,” said Doug Muzyka, Chair of the Board of Directors. “His deep industry experience, operational discipline, and clear understanding of the BMC’s national mandate position him well to lead the organization into its next phase of execution and long‑term sustainability.”
Mr. Sheldon brings more than 40 years of leadership experience in the biotechnology and pharmaceutical sectors, having held senior executive roles at SmithKline Beecham, Rhône‑Merieux, Shire Biochem, where he negociated the first canadian pandemic vaccine program, and Medicago. As President and CEO of Medicago from 2003 to 2017, he led the planning, development and validation of vaccine manufacturing facilities in Québec and North Carolina and oversaw significant organizational growth.
Since joining the BMC, Mr. Sheldon has overseen key milestones, including progress toward operational sustainability, readiness for Phase 3 manufacturing, and the Centre’s expanding role in Canada’s pandemic preparedness ecosystem.
The Board also announced the appointment of Elizabeth Douville as Vice President, Corporate Development, further strengthening the BMC’s executive team.
“We are very pleased to welcome Dr. Elizabeth Douville to the executive team” said Andy Sheldon President and CEO. “Elizabeth’s vast experience in venture capital and her proven track record in translating academic research and development into commercial success will be instrumental as the BMC expands its strategic partnerships and role within Canada’s life sciences ecosystem.”
Dr. Douville is a seasoned life sciences executive with long standing experience in venture capital financing, biotech innovation, and partnerships. She last served as President and Chief Executive Officer of IRICoR, a drug discovery commercialization centre based at the Université de Montréal, and previously founded AmorChem, an early‑stage venture capital fund focused on translating academic research into biotechnology companies.
Dr. Douville earned a Ph.D. in Biochemistry from the University of Ottawa followed by postdoctoral fellowships in the United Kingdom. She also holds the ICD.D designation from the Institute of Corporate Directors, reflecting her commitment to excellence in corporate governance.
The Biologics Manufacturing Centre (BMC) Inc. is dedicated to strengthening Canada’s biomanufacturing capacity and supporting national preparedness for public health emergencies through strong operational execution and strategic partnerships.
In addition to its manufacturing mandate, the BMC plays an active role in supporting Canada’s biotechnology sector through collaboration, partnerships, and workforce development. The BMC works closely with academic institutions, industry partners and public sector organizations to enable technology transfer, build biomanufacturing expertise, and support the development of skilled talent required to strengthen Canada’s life sciences ecosystem.
These leadership appointments reflect the Board’s confidence in the BMC’s strategic direction and its continued commitment to strong governance and execution of its national biomanufacturing mission.
About the Biologics Manufacturing Centre (BMC) Inc.
Based in Ville Mont-Royal, the BMC is a non-profit organization dedicated to the production of innovative biologic solutions. Its mission is to facilitate access to high-quality, affordable, and sustainable biologic therapies, while fostering innovation in rare and infectious diseases. The BMC is committed to building a robust and collaborative ecosystem to strengthen resilience against emerging health threats and promote health equity.
For more information:
Biologics Manufacturing Centre (BMC) Inc.